M. Abdullaev, B. Kantemirova, E. Chernysheva, A. Romanova
{"title":"个体化抗血小板治疗的成本-效用分析","authors":"M. Abdullaev, B. Kantemirova, E. Chernysheva, A. Romanova","doi":"10.29039/2712-8164-2023-1-17-26","DOIUrl":null,"url":null,"abstract":"The article contains the results of a comparison pharmacoeconomical cost-utility analysis of several options for dual antiplatelet therapy in patients with acute coronary syndrome after stent implanting. The costs for treatment alternatives with and without prior pharmacogenetic testing for CYP2C19 were calculated. According to the results of the analysis the most cost-effective treatment option for patients with acute coronary syndrome is prior pharmacogenetic testing and the choice of the antiplatelet drug prasugrel in slow and intermediate metabolizers (CUA: 289,111.00 rubles per QALY).","PeriodicalId":269283,"journal":{"name":"ASTRAKHAN MEDICAL JOURNAL","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"COST-UTILITY ANALYSIS OF PERSONALIZED ANTIPLATELET THERAPY\",\"authors\":\"M. Abdullaev, B. Kantemirova, E. Chernysheva, A. Romanova\",\"doi\":\"10.29039/2712-8164-2023-1-17-26\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The article contains the results of a comparison pharmacoeconomical cost-utility analysis of several options for dual antiplatelet therapy in patients with acute coronary syndrome after stent implanting. The costs for treatment alternatives with and without prior pharmacogenetic testing for CYP2C19 were calculated. According to the results of the analysis the most cost-effective treatment option for patients with acute coronary syndrome is prior pharmacogenetic testing and the choice of the antiplatelet drug prasugrel in slow and intermediate metabolizers (CUA: 289,111.00 rubles per QALY).\",\"PeriodicalId\":269283,\"journal\":{\"name\":\"ASTRAKHAN MEDICAL JOURNAL\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-05-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ASTRAKHAN MEDICAL JOURNAL\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.29039/2712-8164-2023-1-17-26\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ASTRAKHAN MEDICAL JOURNAL","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29039/2712-8164-2023-1-17-26","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
COST-UTILITY ANALYSIS OF PERSONALIZED ANTIPLATELET THERAPY
The article contains the results of a comparison pharmacoeconomical cost-utility analysis of several options for dual antiplatelet therapy in patients with acute coronary syndrome after stent implanting. The costs for treatment alternatives with and without prior pharmacogenetic testing for CYP2C19 were calculated. According to the results of the analysis the most cost-effective treatment option for patients with acute coronary syndrome is prior pharmacogenetic testing and the choice of the antiplatelet drug prasugrel in slow and intermediate metabolizers (CUA: 289,111.00 rubles per QALY).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
